Baycol LogoChemical structure of cerivastatin
Find information on thousands of medical conditions and prescription drugs.

Cerivastatin

In pharmacology, cerivastatin (Baycol®, Lipobay®) is a synthetic member of the class of statins, used to lower cholesterol and prevent cardiovascular disease. It was withdrawn from the market in 2001 because of the high rate of serious side-effects. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Cerivastatin was marketed by the pharmaceutical company Bayer A.G. in the late 1990s as a new synthetic statin, to compete with Pfizer's highly successful Lipitor®.

During post-marketing surveillance, 52 deaths were reported in patients using cerivastatin, mainly from rhabdomyolysis and its resultant renal failure. Risks were higher in patients using fibrates (mainly gemfibrozil/Lopid®) and in patients using the high (0.8 mg/day) dose of cerivastatin. Another 385 nonfatal cases of rhabdomyolysis were reported. This put the risk of this (rare) complication at 5-10 times that of the other statins.

In 2001, Bayer announced the voluntary withdrawal of the drug from the market.

Important Note

On August 8, 2001 the U.S. Food and Drug Administration FDA announced that Bayer Pharmaceutical Division is voluntarily withdrawing Baycol (cerivastatin) from the U.S. market because of reports of sometimes fatal rhabdomyolysis, a severe muscle adverse reaction from this cholesterol-lowering (lipid-lowering) product . The FDA agrees with and supports this decision. All patients taking Baycol should contact their healthcare providers to discuss treatment alternatives.

Read more at Wikipedia.org


[List your site here Free!]


FDA approves new dose of cerivastatin
From Nurse Practitioner, 8/1/99

The FDA has approved a 0.4-mg dose of Bayer Corporation's cerivastatin (Baycol) for patients with primary hypercholesterolemia and mixed dyslipidemia. Additionally, the statin was approved to reduce triglycerides and apolipoprotein B (apo B) in patients with primary hypercholesterolemia and mixed dyslipidemia. Cerivastatin was initially approved at 0.2-mg and 0.3-mg strengths. Cerivastatin was previously approved as an adjunct to diet for the reduction of elevated total cholesterol and lowdensity lipoprotein cholesterol (LDLC) in patients with hypercholesterolemia and mixed dyslipidemia when the response to dietary restriction of saturated fat and cholesterol and other nonpharmacologic measures was inadequate.

Clinical data from two large trials of patients with hypercholesterolemia showed that patients taking the 0.4-mg dose of cerivastatin each day for 8 weeks (in conjunction with dietary therapy) achieved mean reductions in LDL-C and total cholesterol of 34% and 24%, respectively. Reductions in apo B of 26% were observed. Pooled data from seven studies of patients treated with cerivastatin 0.4 mg for 8 weeks found a median triglyceride reduction from baseline of 30%.

Liver function tests are recommended before treatment with cerivastatin, at 6 and 12 weeks after beginning therapy or elevating the dose, and periodically thereafter, the labeling states. The drug should not be used in patients with active liver disease or unexplained and persistent elevations of serum transaminase, in women during pregnancy, and in breast-feeding women.

Copyright Springhouse Corporation Aug 1999
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Cerivastatin
Home Contact Resources Exchange Links ebay